 <h1>Insulin aspart Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of insulin aspart include:</b> hypoglycemia.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to insulin aspart: solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, insulin aspart may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking insulin aspart:</p><p>
<i>More common</i>
</p><ul>
<li>Anxiety</li>
<li>behavior change similar to being drunk</li>
<li>bladder pain</li>
<li>bloody or cloudy urine</li>
<li>blurred vision</li>
<li>cold sweats</li>
<li>confusion</li>
<li>depression</li>
<li>difficult, burning, or painful urination</li>
<li>difficulty with thinking</li>
<li>dizziness or lightheadedness</li>
<li>drowsiness</li>
<li>excessive hunger</li>
<li>fast heartbeat</li>
<li>frequent urge to urinate</li>
<li>headache</li>
<li>irritability or abnormal behavior</li>
<li>lower back or side pain</li>
<li>nightmares</li>
<li>restless sleep</li>
<li>seizures</li>
<li>shakiness</li>
<li>slurred speech</li>
<li>tingling in the hands, feet, lips, or tongue</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Depression of the skin at the place of injection</li>
<li>dryness of the mouth</li>
<li>fast or weak pulse</li>
<li>feeling of pressure, itching, redness, soreness, stinging, swelling, or tingling at the place of injection</li>
<li>increased thirst</li>
<li>irregular heartbeat</li>
<li>loss of appetite</li>
<li>mood or mental changes</li>
<li>muscle cramps or pain</li>
<li>nausea</li>
<li>skin rash or itching over the whole body</li>
<li>sweating</li>
<li>thickening of the skin at the place of injection</li>
<li>trouble breathing</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>difficulty in breathing or swallowing</li>
<li>rapid weight gain</li>
<li>redistribution or accumulation of body fat</li>
<li>swelling of the face, throat, or tongue</li>
<li>unusual weight gain or loss</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of insulin aspart may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>body aches or pain</li>
<li>chills</li>
<li>cough</li>
<li>diarrhea</li>
<li>ear congestion</li>
<li>fever</li>
<li>loss of voice</li>
<li>muscle aches</li>
<li>sneezing</li>
<li>sore throat</li>
<li>stuffy or runny nose</li>
</ul><p>
<!-- end solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to insulin aspart: injectable solution, subcutaneous solution</i></p><h3>General</h3><p>Adverse reactions observed have included hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Very rare</b> (less than 0.01%): Anaphylaxis</p>
<p><b>Common</b> (1% to 10%): Allergic skin manifestations </p>
<p><b>Frequency not reported</b>: Allergic reactions<sup>[Ref]</sup></p><p>Hypersensitivity side effects have included both local and systemic reactions.  Anaphylaxis has been reported.  Local reactions have presented as erythema, local edema, and pruritus at the injection site.  Most minor reactions to insulin at the injection site resolve in a few days to a few weeks.  </p>
<p></p>
<p>Generalized allergy to insulin may present as a whole body rash, dyspnea, wheezing, hypotension, tachycardia, or diaphoresis.  In clinical trials, allergic reactions were reported in 0.7% (10/1394) patients receiving insulin aspart.</p>
<p></p>
<p>Clinical trials with Fiasp(R) reported generalized hypersensitivity reactions at 0.2% (comparator 0.1%).  Anaphylactic reactions were not reported.  Allergic skin manifestations were reported at 1.5% (comparator 1.4%) and included eczema, rash, pruritic rash, urticaria, and dermatitis.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypoglycemia</p>
<p><b>Frequency not reported</b>: Weight gain<sup>[Ref]</sup></p><p>Weight gain has been reported with insulin therapy and has been attributed to the anabolic effects of insulin and the decrease in glucosuria.<sup>[Ref]</sup></p><h3>Local</h3><p>Localized cutaneous amyloidosis at the injection site has been reported with resultant hyperglycemia with repeated insulin injections into that area; hypoglycemia has been reported with a sudden change to an unaffected injection site.</p><p><b>Common</b> (1% to 10%): Injection site reactions (including rash, redness, inflammation, pain, itching, and bruising)</p>
<p><b>Frequency not reported</b>: Lipodystrophy (including lipohypertrophy, lipoatrophy) </p>
<p><b>Postmarketing reports</b>: Localized cutaneous amyloidosis at injection site</p><h3>Cardiovascular</h3><p>Insulin may cause sodium retention and edema, especially as metabolic control is improving.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Chest pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Peripheral edema<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Long-term use of insulin may cause lipodystrophy at the site of repeated injection.  Lipodystrophy includes lipohypertrophy, a thickening of adipose tissue, and lipoatrophy, thinning of adipose tissue.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Skin disorder, eczema, dermatitis </p>
<p><b>Uncommon</b> (0.1% to 1%): Urticaria, rash </p>
<p><b>Frequency not reported</b>: Lipodystrophy including lipohypertrophy and lipoatrophy<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Onychomycosis </p>
<p><b>Frequency not reported</b>: Anti-insulin antibody titers<sup>[Ref]</sup></p><p>The clinical significance of the development of these antibody titers is unknown.<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Refraction disorder, worsening of diabetic retinopathy<sup>[Ref]</sup></p><p>Rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder and worsening of diabetic retinopathy.  However, long-term glycemic control decreases the risk of diabetic retinopathy.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Rapid improvement in glucose control has been associated with a transitory, reversible acute painful peripheral neuropathy.  However, long-term glycemic control decreases the risk.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Headache (up to 12%)</p>
<p><b>Common</b> (1% to 10%): Hyporeflexia, sensory disturbance</p>
<p><b>Rare</b> (less than 0.1%): Painful peripheral neuropathy<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, diarrhea, abdominal pain<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Nasopharyngitis (23%)</p>
<p><b>Common</b> (1% to 10%): Upper respiratory infection<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Novolog (insulin aspart)" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ. </p><p id="ref_2">2. "Product Information. Fiasp (insulin aspart)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Humalog vs Novolog (Novalog): What's the difference?</li>
<li>What is the difference between Fiasp and NovoLog?</li>
<li>What are the ingredient drugs in Ryzodeg 70/30?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about insulin aspart</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>24 Reviews</li>
<li>Drug class: insulin</li>
<li>FDA Alerts (1)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Insulin aspart, recombinant Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Novolog, Fiasp, NovoLog FlexPen, NovoLog PenFill</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +3 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Diabetes, Type 2</li>
<li>Diabetes, Type 1</li>
<li>Diabetic Ketoacidosis</li>
<li>Nonketotic Hyperosmolar Syndrome</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to insulin aspart: injectable solution, subcutaneous solution</i></p><h3>General</h3><p>Adverse reactions observed have included hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Very rare</b> (less than 0.01%): Anaphylaxis</p><p><b>Common</b> (1% to 10%): Allergic skin manifestations </p><p><b>Frequency not reported</b>: Allergic reactions<sup>[Ref]</sup></p><p>Hypersensitivity side effects have included both local and systemic reactions.  Anaphylaxis has been reported.  Local reactions have presented as erythema, local edema, and pruritus at the injection site.  Most minor reactions to insulin at the injection site resolve in a few days to a few weeks.  </p><p></p><p>Generalized allergy to insulin may present as a whole body rash, dyspnea, wheezing, hypotension, tachycardia, or diaphoresis.  In clinical trials, allergic reactions were reported in 0.7% (10/1394) patients receiving insulin aspart.</p><p></p><p>Clinical trials with Fiasp(R) reported generalized hypersensitivity reactions at 0.2% (comparator 0.1%).  Anaphylactic reactions were not reported.  Allergic skin manifestations were reported at 1.5% (comparator 1.4%) and included eczema, rash, pruritic rash, urticaria, and dermatitis.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypoglycemia</p><p><b>Frequency not reported</b>: Weight gain<sup>[Ref]</sup></p><p>Weight gain has been reported with insulin therapy and has been attributed to the anabolic effects of insulin and the decrease in glucosuria.<sup>[Ref]</sup></p><h3>Local</h3><p>Localized cutaneous amyloidosis at the injection site has been reported with resultant hyperglycemia with repeated insulin injections into that area; hypoglycemia has been reported with a sudden change to an unaffected injection site.</p><p><b>Common</b> (1% to 10%): Injection site reactions (including rash, redness, inflammation, pain, itching, and bruising)</p><p><b>Frequency not reported</b>: Lipodystrophy (including lipohypertrophy, lipoatrophy) </p><p><b>Postmarketing reports</b>: Localized cutaneous amyloidosis at injection site</p><h3>Cardiovascular</h3><p>Insulin may cause sodium retention and edema, especially as metabolic control is improving.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Chest pain</p><p><b>Uncommon</b> (0.1% to 1%): Peripheral edema<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Long-term use of insulin may cause lipodystrophy at the site of repeated injection.  Lipodystrophy includes lipohypertrophy, a thickening of adipose tissue, and lipoatrophy, thinning of adipose tissue.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Skin disorder, eczema, dermatitis </p><p><b>Uncommon</b> (0.1% to 1%): Urticaria, rash </p><p><b>Frequency not reported</b>: Lipodystrophy including lipohypertrophy and lipoatrophy<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Onychomycosis </p><p><b>Frequency not reported</b>: Anti-insulin antibody titers<sup>[Ref]</sup></p><p>The clinical significance of the development of these antibody titers is unknown.<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Refraction disorder, worsening of diabetic retinopathy<sup>[Ref]</sup></p><p>Rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder and worsening of diabetic retinopathy.  However, long-term glycemic control decreases the risk of diabetic retinopathy.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Rapid improvement in glucose control has been associated with a transitory, reversible acute painful peripheral neuropathy.  However, long-term glycemic control decreases the risk.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Headache (up to 12%)</p><p><b>Common</b> (1% to 10%): Hyporeflexia, sensory disturbance</p><p><b>Rare</b> (less than 0.1%): Painful peripheral neuropathy<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, diarrhea, abdominal pain<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Nasopharyngitis (23%)</p><p><b>Common</b> (1% to 10%): Upper respiratory infection<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Novolog (insulin aspart)" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ. </p><p id="ref_2">2. "Product Information. Fiasp (insulin aspart)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Humalog vs Novolog (Novalog): What's the difference?</li>
<li>What is the difference between Fiasp and NovoLog?</li>
<li>What are the ingredient drugs in Ryzodeg 70/30?</li>
</ul><h2>More about insulin aspart</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>24 Reviews</li>
<li>Drug class: insulin</li>
<li>FDA Alerts (1)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Insulin aspart, recombinant Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +3 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Diabetes, Type 2</li>
<li>Diabetes, Type 1</li>
<li>Diabetic Ketoacidosis</li>
<li>Nonketotic Hyperosmolar Syndrome</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>